# Definitive Healthcare Corp.: financial statements, quarterly

DH · Nasdaq · CIK 1861795 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/dh.md) · [Financials](/companies/dh/financials.md) · [Filings](/companies/dh/filings.md) · [Insiders](/companies/dh/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/dh/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [65.3](/filings/0000950170-24-123385.md) | [65.9 d](/filings/0001193125-26-076782.md) | [63.5](/filings/0000950170-25-067044.md) | [63.7](/filings/0000950170-25-105071.md) | [62.7](/filings/0001193125-25-269681.md) | [62.3 d](/filings/0001193125-26-076782.md) | [59.2](/filings/0001193125-26-212063.md) | [60.8](/filings/0001193125-26-342488.md) | [60.0](/filings/0001193125-25-269681.md) | [61.5 d](/filings/0001193125-26-076782.md) | [55.9](/filings/0001193125-26-212063.md) | [55.2](/filings/0001193125-26-342488.md) |
| Cost of revenue | $m | not reported | not reported | [13.1](/filings/0000950170-25-067044.md) | [13.3](/filings/0000950170-25-105071.md) | [13.7](/filings/0001193125-25-269681.md) | [14.7 d](/filings/0001193125-26-076782.md) | [15.4](/filings/0001193125-26-212063.md) | [14.1](/filings/0001193125-26-342488.md) | [14.1](/filings/0001193125-25-269681.md) | [14.6 d](/filings/0001193125-26-076782.md) | [14.3](/filings/0001193125-26-212063.md) | [14.7](/filings/0001193125-26-342488.md) |
| Gross profit | $m | [53.4](/filings/0000950170-24-123385.md) | [53.4 d](/filings/0001193125-26-076782.md) | [50.4](/filings/0000950170-25-067044.md) | [50.5](/filings/0000950170-25-105071.md) | [49.0](/filings/0001193125-25-269681.md) | [47.6 d](/filings/0001193125-26-076782.md) | [43.8](/filings/0001193125-26-212063.md) | [46.6](/filings/0001193125-26-342488.md) | [46.0](/filings/0001193125-25-269681.md) | [46.9 d](/filings/0001193125-26-076782.md) | [41.7](/filings/0001193125-26-212063.md) | [40.5](/filings/0001193125-26-342488.md) |
| Research and development | $m | [10.8](/filings/0000950170-24-123385.md) | [11.6 d](/filings/0001193125-26-076782.md) | [10.1](/filings/0000950170-25-067044.md) | [10.1](/filings/0000950170-25-105071.md) | [7.3](/filings/0001193125-25-269681.md) | [9.0 d](/filings/0001193125-26-076782.md) | [9.3](/filings/0001193125-26-212063.md) | [8.0](/filings/0001193125-26-342488.md) | [7.6](/filings/0001193125-25-269681.md) | [10.0 d](/filings/0001193125-26-076782.md) | [6.5](/filings/0001193125-26-212063.md) | [6.8](/filings/0001193125-26-342488.md) |
| Operating income | $m | [(295)](/filings/0000950170-24-123385.md) | [(10.1) d](/filings/0001193125-26-076782.md) | [(16.2)](/filings/0000950170-25-067044.md) | [(370)](/filings/0000950170-25-105071.md) | [(225)](/filings/0001193125-25-269681.md) | [(99.6) d](/filings/0001193125-26-076782.md) | [(185)](/filings/0001193125-26-212063.md) | [(4.2)](/filings/0001193125-26-342488.md) | [(8.7)](/filings/0001193125-25-269681.md) | [(26.6) d](/filings/0001193125-26-076782.md) | [(201)](/filings/0001193125-26-212063.md) | [(6.7)](/filings/0001193125-26-342488.md) |
| Interest expense | $m | [3.9](/filings/0000950170-24-123385.md) | [3.9 d](/filings/0001193125-26-076782.md) | [3.8](/filings/0000950170-25-067044.md) | [3.8](/filings/0000950170-25-105071.md) | [3.7](/filings/0001193125-25-269681.md) | [3.5 d](/filings/0001193125-26-076782.md) | [2.4](/filings/0001193125-26-212063.md) | [3.0](/filings/0001193125-26-342488.md) | [3.0](/filings/0001193125-25-269681.md) | [2.9 d](/filings/0001193125-26-076782.md) | [2.6](/filings/0001193125-26-212063.md) | [2.6](/filings/0001193125-26-342488.md) |
| Income tax | $m | [(17.5)](/filings/0000950170-24-123385.md) | [1.2 d](/filings/0001193125-26-076782.md) | [(0.8)](/filings/0000950170-25-067044.md) | [(21.9)](/filings/0000950170-25-105071.md) | [(13.7)](/filings/0001193125-25-269681.md) | [(5.9) d](/filings/0001193125-26-076782.md) | [(10.9)](/filings/0001193125-26-212063.md) | [0.5](/filings/0001193125-26-342488.md) | [0.5](/filings/0001193125-25-269681.md) | [(0.1) d](/filings/0001193125-26-076782.md) | [(3.4)](/filings/0001193125-26-212063.md) | [(0.3)](/filings/0001193125-26-342488.md) |
| Net income | $m | [(172)](/filings/0000950170-24-123385.md) | [(10.2) d](/filings/0001193125-26-076782.md) | [(9.5)](/filings/0000950170-25-067044.md) | [(214)](/filings/0000950170-25-105071.md) | [(131)](/filings/0001193125-25-269681.md) | [(59.1) d](/filings/0001193125-26-076782.md) | [(107)](/filings/0001193125-26-212063.md) | [(7.6)](/filings/0001193125-26-342488.md) | [(14.8)](/filings/0001193125-25-269681.md) | [(9.3) d](/filings/0001193125-26-076782.md) | [(139)](/filings/0001193125-26-212063.md) | [(5.4)](/filings/0001193125-26-342488.md) |
| Diluted EPS | $ per share | [(1.50)](/filings/0000950170-24-123385.md) | not reported | [(0.08)](/filings/0000950170-25-067044.md) | [(1.81)](/filings/0000950170-25-105071.md) | [(1.12)](/filings/0001193125-25-269681.md) | not reported | [(0.95)](/filings/0001193125-26-212063.md) | [(0.07)](/filings/0001193125-26-342488.md) | [(0.14)](/filings/0001193125-25-269681.md) | not reported | [(1.32)](/filings/0001193125-26-212063.md) | [(0.05)](/filings/0001193125-26-342488.md) |
| Basic EPS | $ per share | [(1.50)](/filings/0000950170-24-123385.md) | not reported | [(0.08)](/filings/0000950170-25-067044.md) | [(1.81)](/filings/0000950170-25-105071.md) | [(1.12)](/filings/0001193125-25-269681.md) | not reported | [(0.95)](/filings/0001193125-26-212063.md) | [(0.07)](/filings/0001193125-26-342488.md) | [(0.14)](/filings/0001193125-25-269681.md) | not reported | [(1.32)](/filings/0001193125-26-212063.md) | [(0.05)](/filings/0001193125-26-342488.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [77.5](/filings/0000950170-23-058257.md) | [131](/filings/0000950170-25-029086.md) | [106](/filings/0000950170-24-054539.md) | [121](/filings/0000950170-24-090808.md) | [138](/filings/0000950170-24-123385.md) | [105](/filings/0001193125-26-076782.md) | [106](/filings/0000950170-25-067044.md) | [81.0](/filings/0000950170-25-105071.md) | [108](/filings/0001193125-25-269681.md) | [164](/filings/0001193125-26-342488.md) | [158](/filings/0001193125-26-212063.md) | [171](/filings/0001193125-26-342488.md) |
| Current assets | $m | [375](/filings/0000950170-23-058257.md) | [394](/filings/0000950170-25-029086.md) | [379](/filings/0000950170-24-054539.md) | [368](/filings/0000950170-24-090808.md) | [369](/filings/0000950170-24-123385.md) | [370](/filings/0001193125-26-076782.md) | [273](/filings/0000950170-25-067044.md) | [249](/filings/0000950170-25-105071.md) | [246](/filings/0001193125-25-269681.md) | [258](/filings/0001193125-26-342488.md) | [246](/filings/0001193125-26-212063.md) | [240](/filings/0001193125-26-342488.md) |
| Total assets | $m | [1,820](/filings/0000950170-23-058257.md) | [1,826](/filings/0000950170-25-029086.md) | [1,810](/filings/0000950170-24-054539.md) | [1,422](/filings/0000950170-24-090808.md) | [1,182](/filings/0000950170-24-123385.md) | [1,089](/filings/0001193125-26-076782.md) | [809](/filings/0000950170-25-067044.md) | [770](/filings/0000950170-25-105071.md) | [756](/filings/0001193125-25-269681.md) | [735](/filings/0001193125-26-342488.md) | [515](/filings/0001193125-26-212063.md) | [497](/filings/0001193125-26-342488.md) |
| Current liabilities | $m | [147](/filings/0000950170-23-058257.md) | [171](/filings/0000950170-25-029086.md) | [165](/filings/0000950170-24-054539.md) | [153](/filings/0000950170-24-090808.md) | [148](/filings/0000950170-24-123385.md) | [161](/filings/0001193125-26-076782.md) | [156](/filings/0000950170-25-067044.md) | [151](/filings/0000950170-25-105071.md) | [154](/filings/0001193125-25-269681.md) | [157](/filings/0001193125-26-342488.md) | [140](/filings/0001193125-26-212063.md) | [129](/filings/0001193125-26-342488.md) |
| Total liabilities | $m | [616](/filings/0000950170-23-058257.md) | [627](/filings/0000950170-25-029086.md) | [615](/filings/0000950170-24-054539.md) | [536](/filings/0000950170-24-090808.md) | [486](/filings/0000950170-24-123385.md) | [482](/filings/0001193125-26-076782.md) | [373](/filings/0000950170-25-067044.md) | [359](/filings/0000950170-25-105071.md) | [366](/filings/0001193125-25-269681.md) | [357](/filings/0001193125-26-342488.md) | [324](/filings/0001193125-26-212063.md) | [309](/filings/0001193125-26-342488.md) |
| Long-term debt | $m | [246](/filings/0000950170-23-058257.md) | [243](/filings/0000950170-25-029086.md) | [239](/filings/0000950170-24-054539.md) | [236](/filings/0000950170-24-090808.md) | [233](/filings/0000950170-24-123385.md) | [229](/filings/0001193125-26-076782.md) | [162](/filings/0000950170-25-067044.md) | [160](/filings/0000950170-25-105071.md) | [158](/filings/0001193125-25-269681.md) | [156](/filings/0001193125-26-342488.md) | [154](/filings/0001193125-26-212063.md) | [152](/filings/0001193125-26-342488.md) |
| Current portion of debt | $m | [13.8](/filings/0000950170-23-058257.md) | [13.8](/filings/0000950170-25-029086.md) | [13.8](/filings/0000950170-24-054539.md) | [13.8](/filings/0000950170-24-090808.md) | [13.8](/filings/0000950170-24-123385.md) | [13.8](/filings/0001193125-26-076782.md) | [8.8](/filings/0000950170-25-067044.md) | [8.8](/filings/0000950170-25-105071.md) | [8.8](/filings/0001193125-25-269681.md) | [8.8](/filings/0001193125-26-342488.md) | [8.8](/filings/0001193125-26-212063.md) | [8.8](/filings/0001193125-26-342488.md) |
| Shareholders' equity | $m | [1,203](/filings/0000950170-23-058257.md) | [1,199](/filings/0000950170-25-029086.md) | [1,195](/filings/0000950170-24-054539.md) | [886](/filings/0000950170-24-090808.md) | [696](/filings/0000950170-24-123385.md) | [607](/filings/0001193125-26-076782.md) | [436](/filings/0000950170-25-067044.md) | [411](/filings/0000950170-25-105071.md) | [390](/filings/0001193125-25-269681.md) | [379](/filings/0001193125-26-342488.md) | [191](/filings/0001193125-26-212063.md) | [188](/filings/0001193125-26-342488.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [9.5 d](/filings/0000950170-24-123385.md) | [4.7 d](/filings/0001193125-26-076782.md) | [16.6](/filings/0000950170-25-067044.md) | [14.0 d](/filings/0000950170-25-105071.md) | [19.4 d](/filings/0001193125-25-269681.md) | [8.1 d](/filings/0001193125-26-076782.md) | [26.1](/filings/0001193125-26-212063.md) | [9.3 d](/filings/0001193125-26-342488.md) | [15.7 d](/filings/0001193125-25-269681.md) | [2.7 d](/filings/0001193125-26-076782.md) | [11.6](/filings/0001193125-26-212063.md) | [11.5 d](/filings/0001193125-26-342488.md) |
| Capital expenditure | $m | [0.3 d](/filings/0000950170-24-123385.md) | [0.6 d](/filings/0001193125-26-076782.md) | [0.3](/filings/0000950170-25-067044.md) | [0.4 d](/filings/0000950170-25-105071.md) | [0.8 d](/filings/0001193125-25-269681.md) | [10.9 d](/filings/0001193125-26-076782.md) | [7.7](/filings/0001193125-26-212063.md) | [2.3 d](/filings/0001193125-26-342488.md) | [2.3 d](/filings/0001193125-25-269681.md) | [4.4 d](/filings/0001193125-26-076782.md) | [3.2](/filings/0001193125-26-212063.md) | [2.9 d](/filings/0001193125-26-342488.md) |
| Share repurchases | $m | [0.0 d](/filings/0000950170-24-123385.md) | [0.0 d](/filings/0001193125-26-076782.md) | [0.0](/filings/0000950170-25-067044.md) | [7.0 d](/filings/0000950170-25-105071.md) | [8.0 d](/filings/0001193125-25-269681.md) | [7.3 d](/filings/0001193125-26-076782.md) | [21.2](/filings/0001193125-26-212063.md) | [19.1 d](/filings/0001193125-26-342488.md) | [9.2 d](/filings/0001193125-25-269681.md) | [0.0 d](/filings/0001193125-26-076782.md) | [0.0](/filings/0001193125-26-212063.md) | [0.0 d](/filings/0001193125-26-342488.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q4 FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [154](/filings/0000950170-23-042369.md) | [108](/filings/0000950170-24-054539.md) | [112](/filings/0000950170-24-090808.md) | [115](/filings/0000950170-24-123385.md) | [117](/filings/0000950170-25-067044.md) | [118](/filings/0000950170-25-105071.md) | [116](/filings/0001193125-25-269681.md) | [113](/filings/0001193125-26-212063.md) | [107](/filings/0001193125-26-342488.md) | [104](/filings/0001193125-25-269681.md) | [105](/filings/0001193125-26-212063.md) | [106](/filings/0001193125-26-342488.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 106,744,713 at 2026-08-06, from the cover of the [10-Q filed 2026-08-10](/filings/0001193125-26-342488.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.